ZA200201518B - Dispersion formulations containing lipase inhibitors. - Google Patents

Dispersion formulations containing lipase inhibitors.

Info

Publication number
ZA200201518B
ZA200201518B ZA200201518A ZA200201518A ZA200201518B ZA 200201518 B ZA200201518 B ZA 200201518B ZA 200201518 A ZA200201518 A ZA 200201518A ZA 200201518 A ZA200201518 A ZA 200201518A ZA 200201518 B ZA200201518 B ZA 200201518B
Authority
ZA
South Africa
Prior art keywords
formulations containing
lipase inhibitors
dispersion formulations
containing lipase
dispersion
Prior art date
Application number
ZA200201518A
Other languages
English (en)
Inventor
Passchier Christiaan De Smidt
Paul Hadvary
Hans Lengsfeld
Thomas Rades
Hans Steffen
Joseph Tardio
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200201518(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200201518B publication Critical patent/ZA200201518B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA200201518A 1999-09-13 2002-02-22 Dispersion formulations containing lipase inhibitors. ZA200201518B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99118180 1999-09-13

Publications (1)

Publication Number Publication Date
ZA200201518B true ZA200201518B (en) 2003-07-30

Family

ID=8238990

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200201518A ZA200201518B (en) 1999-09-13 2002-02-22 Dispersion formulations containing lipase inhibitors.

Country Status (38)

Country Link
US (3) US20030181512A1 (cs)
EP (1) EP1216025B1 (cs)
JP (1) JP4217016B2 (cs)
KR (1) KR100572434B1 (cs)
CN (1) CN1197551C (cs)
AR (1) AR025587A1 (cs)
AT (1) ATE333866T1 (cs)
AU (1) AU769415B2 (cs)
BR (2) BRPI0013939B1 (cs)
CA (1) CA2383916C (cs)
CO (1) CO5180587A1 (cs)
CY (1) CY1106180T1 (cs)
CZ (1) CZ301901B6 (cs)
DE (1) DE60029602T2 (cs)
DK (1) DK1216025T3 (cs)
EG (1) EG24117A (cs)
ES (1) ES2267563T3 (cs)
HR (1) HRP20020205B1 (cs)
HU (1) HU228858B1 (cs)
IL (1) IL148494A0 (cs)
JO (1) JO2386B1 (cs)
MA (1) MA26818A1 (cs)
ME (1) ME00674B (cs)
MX (1) MXPA02002034A (cs)
MY (1) MY130200A (cs)
NO (1) NO331906B1 (cs)
NZ (1) NZ517545A (cs)
PE (1) PE20010595A1 (cs)
PL (1) PL199870B1 (cs)
PT (1) PT1216025E (cs)
RS (1) RS50422B (cs)
RU (1) RU2239428C2 (cs)
SI (1) SI1216025T1 (cs)
TR (1) TR200200606T2 (cs)
TW (1) TWI243060B (cs)
UY (1) UY26338A1 (cs)
WO (1) WO2001019340A1 (cs)
ZA (1) ZA200201518B (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1307264E (pt) * 2000-07-28 2005-02-28 Hoffmann La Roche Nova composicao farmaceutica
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
FI20045076A7 (fi) * 2004-03-15 2005-09-16 Bioferme Oy Funktionaalinen elintarvike
US8241664B2 (en) * 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
SI1897558T1 (sl) * 2005-06-09 2014-03-31 Norgine Bv Trden pripravek 2-heksadeciloksi-6-metil-4h-3,1-benzoksazin-e-on
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
KR101252635B1 (ko) * 2006-04-20 2013-04-10 (주)아모레퍼시픽 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
EP1970051A1 (en) * 2007-03-14 2008-09-17 Merz Pharma GmbH & Co.KGaA Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases
KR101439470B1 (ko) * 2007-05-22 2014-09-16 한미사이언스 주식회사 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물
ES2350798T3 (es) * 2007-09-12 2011-01-27 Mader S.R.L. Composiciones farmacéuticas para uso oral para tratar a pacientes afectados por la obesidad.
EP2044930A1 (en) * 2007-10-01 2009-04-08 Nestec S.A. Composition for controlling lipase catalyzed reactions
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
KR20100075260A (ko) * 2008-12-24 2010-07-02 주식회사종근당 리파아제 저해제의 부작용 개선을 위한 신규한 약제학적 조성물
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
WO2016166767A1 (en) * 2015-04-14 2016-10-20 Zim Laboratories Limited Pharmaceutical formulation comprising low melting, highly lipophilic drugs
CN106310287B (zh) * 2015-06-25 2019-03-19 山东省药学科学院 新利司他药用组合物及其制备方法
MY196635A (en) * 2018-06-22 2023-04-25 Sime Darby Plantation Intellectual Property Sdn Bhd Method For Reducing Formation of Free Fatty Acids in Plants
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺
CN114983938A (zh) * 2022-05-19 2022-09-02 广东嘉博制药有限公司 一种奥利司他口服复合乳液及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
DE3887179T2 (de) * 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
SU1510148A1 (ru) * 1988-01-26 1995-04-30 Всесоюзный научно-исследовательский институт химии и технологии лекарственных средств Способ получения ингибитора липазы
CA2128044C (en) 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
IT1282673B1 (it) 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
JP2001523221A (ja) 1996-09-01 2001-11-20 ファーモス コーポレイション 親油性物質の促進された生物学的利用能のための固形共沈物
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
WO1998034630A1 (en) * 1997-02-05 1998-08-13 F.Hoffmann-La Roche Ag Use of gastrointestinal lipase inhibitors
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
AU761351B2 (en) 1998-08-14 2003-06-05 Cheplapharm Arzneimittel Gmbh Pharmaceutical compositions containing lipase inhibitors
KR20010079636A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물
US6368622B2 (en) * 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption

Also Published As

Publication number Publication date
AR025587A1 (es) 2002-12-04
ATE333866T1 (de) 2006-08-15
CZ20021276A3 (cs) 2003-04-16
PE20010595A1 (es) 2001-05-26
MY130200A (en) 2007-06-29
NO331906B1 (no) 2012-04-30
NO20021204D0 (no) 2002-03-12
HRP20020205B1 (hr) 2011-06-30
SI1216025T1 (sl) 2006-12-31
MEP90808A (en) 2011-12-20
HUP0202737A2 (hu) 2003-01-28
CA2383916C (en) 2009-01-20
CN1197551C (zh) 2005-04-20
DE60029602T2 (de) 2007-07-26
RS50422B (sr) 2009-12-31
RU2239428C2 (ru) 2004-11-10
HU228858B1 (en) 2013-06-28
TR200200606T2 (tr) 2002-07-22
JP4217016B2 (ja) 2009-01-28
US20110275706A1 (en) 2011-11-10
WO2001019340A1 (en) 2001-03-22
DK1216025T3 (da) 2006-10-30
TWI243060B (en) 2005-11-11
CO5180587A1 (es) 2002-07-30
EP1216025B1 (en) 2006-07-26
BR0013939A (pt) 2002-05-14
DE60029602D1 (de) 2006-09-07
HRP20020205A2 (en) 2004-04-30
PL356174A1 (en) 2004-06-14
KR20020063852A (ko) 2002-08-05
HUP0202737A3 (en) 2005-01-28
US20040175420A1 (en) 2004-09-09
CY1106180T1 (el) 2011-06-08
UY26338A1 (es) 2000-10-31
JO2386B1 (en) 2007-06-17
IL148494A0 (en) 2002-09-12
JP2003509357A (ja) 2003-03-11
HK1049966A1 (en) 2003-06-06
AU769415B2 (en) 2004-01-29
CA2383916A1 (en) 2001-03-22
US20030181512A1 (en) 2003-09-25
CN1373656A (zh) 2002-10-09
KR100572434B1 (ko) 2006-04-18
EG24117A (en) 2008-07-06
YU17202A (sh) 2006-01-16
MXPA02002034A (es) 2002-08-20
AU7286300A (en) 2001-04-17
NO20021204L (no) 2002-03-12
BRPI0013939B1 (pt) 2017-07-18
MA26818A1 (fr) 2004-12-20
ES2267563T3 (es) 2007-03-16
NZ517545A (en) 2003-11-28
PT1216025E (pt) 2006-12-29
ME00674B (me) 2011-12-20
CZ301901B6 (cs) 2010-07-28
US8012494B2 (en) 2011-09-06
PL199870B1 (pl) 2008-11-28
EP1216025A1 (en) 2002-06-26

Similar Documents

Publication Publication Date Title
ZA200201518B (en) Dispersion formulations containing lipase inhibitors.
ZA200109890B (en) Metalloprotease inhibitors.
AU7068600A (en) Encrypted coupons
ZA993938B (en) Ziprasidone formulations.
ZA991975B (en) Enzyme inhibitors.
GB9928968D0 (en) Enzyme
HUP0301349A3 (en) Formulations for il-11
AU5270499A (en) Formulations having probiotically active microorganisms
AU2001263839A1 (en) Liquid formulations
MXPA02003232A (es) Composiciones y metodos para alternar la expresion de genes.
IL148275A0 (en) Substituted 3-phenyl-5-alkoxy-1, 3, 4-oxdiazol-2-ones- and their use as lipase inhibitors
AU7126900A (en) Enzyme inhibitors
GB9924522D0 (en) Enzyme inhibitors
AU3235100A (en) Prothease inhibitors
GB9906245D0 (en) Enzyme
AU2002400A (en) Telomerase inhibitors
AU7127000A (en) Enzyme inhibitors
AU6164800A (en) Level sensor-switch
AU4507001A (en) Enhancing trehalose biosynthesis
GB9924634D0 (en) Enzyme
GB9908458D0 (en) Enzyme
GB2400559B (en) Bacillus anthracis exoantigens
HK1061257A (en) Formulations for il-11
AUPQ173999A0 (en) Phyto-protective formulations
AUPP975199A0 (en) Stumpy level